CANCER:

Esophageal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Esophageal Squamous Cell Carcinoma (69)

Esophageal Adenocarcinoma (29)

Esophageal Squamous Cell Carcinoma (69)

Esophageal Adenocarcinoma (29)

›

No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD8 expression	Esophageal Squamous Cell Carcinoma	CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression	Esophageal Squamous Cell Carcinoma	SLFN11 expression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3wk	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : C1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : C1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : C1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : C1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : C1	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : C1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	XP Sensitive: A2 - Guideline XP Sensitive : A2	XP Sensitive: A2 - Guideline XP Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : C1	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : C1
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : C1	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : C1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	5-fluorouracil + irinotecan Sensitive: A2 - Guideline 5-fluorouracil + irinotecan Sensitive : A2	5-fluorouracil + irinotecan Sensitive: A2 - Guideline 5-fluorouracil + irinotecan Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	IP Sensitive: A2 - Guideline IP Sensitive : A2	IP Sensitive: A2 - Guideline IP Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2
NTRK3 fusion	Esophageal Cancer	NTRK3 fusion	Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : C1	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : C1
NTRK2 fusion	Esophageal Cancer	NTRK2 fusion	Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : C1	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : C1
NTRK1 fusion	Esophageal Cancer	NTRK1 fusion	Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : C1	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : C1
NTRK3 fusion	Esophageal Cancer	NTRK3 fusion	Esophageal Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : C1	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : C1
NTRK2 fusion	Esophageal Cancer	NTRK2 fusion	Esophageal Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : C1	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : C1

Esophageal Cancer

Associations(155)

Associations
(155)